RE: The week's wrap-upjtp
Thanks for the dose of reality; you forget to mention this:
https://www.nuvoresearch.com/documents/2008-07-31%20Q2_Nuvo%20Report%20Final.pdf
"...The Company has incurred substantial losses since its inception as it has invested
significantly in drug development activities and other legacy ventures. At June 30, 2008
the Company had an accumulated deficit of $194.2 million including losses of
approximately $2.9 million and $5.1 million for the three and six–months ended June 30,
2008. At June 30, 2008 the Company had cash and cash equivalents of $17.3 million.
The Company expects that it will continue to incur losses as it expands research and
development activities, its pipeline and works toward the approval of Pennsaid in the
United States.
Even though management believes the cash resources currently
available to the Company are sufficient to execute its 2008 plan, the Company’s ability to
continue as a going concern and to expand its product pipeline depends on its ability to
secure additional licensing fees, secure co-development agreements, obtain additional
capital and ultimately achieve profitable operations...."
Let's hope the company can survive until Pennsaid receives approval.
Regards
pdm